David J. Owen

University of Queensland — Australia

Materials Science · Physical Sciences

27h-index2.4kcitations95works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Dendrimers and Hyperbranched Polymers(17), RNA Interference and Gene Delivery(12), Protein Kinase Regulation and GTPase Signaling(6), Cellular transport and secretion(6), Carbohydrate Chemistry and Synthesis(6)

Publications95 total

Initial Investigations into Nanobody Functionalization and Radiolabeling with Astatine-211
Nuclear Medicine and Biology·2025Open Access
Ethics, Untimeliness, and <i>Redlichkeit</i>
2025
Of condensates and coats - reciprocal regulation of clathrin assembly and the growth of protein networks
2025Open Access
Nanobody-Mediated Cellular Uptake Maximizes the Potency of Polylysine Dendrimers While Preserving Solid Tumor Penetration
ACS Nano·2025· 5 cited
BPS2025 - Synergy between liquid networks and solid assemblies in clathrin-mediated endocytosis
Biophysical Journal·2025
In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate
International Journal of Pharmaceutics·2023· 8 citedOpen Access
Subcutaneous delivery of a dendrimer-BH3 mimetic improves lymphatic uptake and survival in lymphoma
Journal of Controlled Release·2022· 15 cited
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy
Communications Biology·2021· 89 citedOpen Access
VPS26 dimer region of metazoan membrane-assembled retromer:SNX3 complex modelled with human proteins
2021
Vps26 dimer region of the fungal membrane-assembled retromer:Grd19 complex.
2021
Abstract 1715: Anti-cancer activity of a SN-38 nanoparticle, DEP® irinotecan, in human colon cancer xenograft models
Cancer Research·2020· 2 cited
Abstract 1718: Design and optimization of a dendrimer-conjugated dual Bcl-2/Bcl-xL inhibitor, AZD0466, with improved therapeutic index
Cancer Research·2020· 2 cited
Abstract 1716: Anticancer activity of the taxane nanoparticles, DEP® docetaxel and DEP® cabazitaxel
Cancer Research·2020· 14 cited
AP2 in clathrin coats assembled on a membrane containing dileucine- and tyrosine-based cargo peptides
2020
Clathrin with bound beta2 appendage of AP2
2020
Reducing Dendrimer Generation and PEG Chain Length Increases Drug Release and Promotes Anticancer Activity of PEGylated Polylysine Dendrimers Conjugated with Doxorubicin via a Cathepsin-Cleavable Peptide Linker
Molecular Pharmaceutics·2018· 52 citedOpen Access
Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats
Journal of Pharmaceutical Sciences·2018· 17 cited
Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site
Nanomedicine Nanotechnology Biology and Medicine·2017· 27 citedOpen Access
Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers
European Journal of Pharmaceutics and Biopharmaceutics·2017· 36 citedOpen Access
A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep
Pharmaceutical Research·2015· 27 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Christopher J. H. Porter(14), Lisa M. Kaminskas(13), Victoria M. McLeod(12), Brian D. Kelly(12), Gemma M. Ryan(6), Lewis N. Mander(6), Herbert Waldmann(5), Mark Williamson(4), Gian Sberna(4), Ben J. Boyd(4), Dharmini Mehta(4), Mark von Itzstein(4), Michelle P. McIntosh(3), Mariana El Sous(3), Georgina A. Holloway(3), Mui Ling Khoo(3), Peter J. Scammells(3), Mark A. Rizzacasa(3), Seth A. Jones(3), Rashmi Pathak(3)